SI3934653T1 - Azelastin za protivirusno zdravljenje - Google Patents
Azelastin za protivirusno zdravljenjeInfo
- Publication number
- SI3934653T1 SI3934653T1 SI202130029T SI202130029T SI3934653T1 SI 3934653 T1 SI3934653 T1 SI 3934653T1 SI 202130029 T SI202130029 T SI 202130029T SI 202130029 T SI202130029 T SI 202130029T SI 3934653 T1 SI3934653 T1 SI 3934653T1
- Authority
- SI
- Slovenia
- Prior art keywords
- azelastine
- antiviral treatment
- antiviral
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20177451 | 2020-05-29 | ||
| EP20184767.0A EP3936132A1 (en) | 2020-07-08 | 2020-07-08 | Azelastine as antiviral treatment |
| EP20195740 | 2020-09-11 | ||
| EP21171333 | 2021-04-29 | ||
| EP21727186.5A EP3934653B1 (en) | 2020-05-29 | 2021-05-28 | Azelastine as antiviral treatment |
| PCT/EP2021/064338 WO2021239943A1 (en) | 2020-05-29 | 2021-05-28 | Azelastine as antiviral treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3934653T1 true SI3934653T1 (sl) | 2023-04-28 |
Family
ID=76059910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202130029T SI3934653T1 (sl) | 2020-05-29 | 2021-05-28 | Azelastin za protivirusno zdravljenje |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20230201216A1 (https=) |
| EP (2) | EP3934653B1 (https=) |
| JP (1) | JP2023529025A (https=) |
| KR (1) | KR20230021009A (https=) |
| CN (1) | CN116406273A (https=) |
| AU (1) | AU2021279280A1 (https=) |
| BR (1) | BR112022023897A2 (https=) |
| CA (1) | CA3184167A1 (https=) |
| DK (1) | DK3934653T3 (https=) |
| ES (1) | ES2937145T3 (https=) |
| FI (1) | FI3934653T3 (https=) |
| HU (1) | HUE060929T2 (https=) |
| IL (1) | IL298543A (https=) |
| JO (1) | JOP20220319B1 (https=) |
| LT (1) | LT3934653T (https=) |
| MX (1) | MX2022015074A (https=) |
| PL (1) | PL3934653T3 (https=) |
| RS (1) | RS63940B1 (https=) |
| SI (1) | SI3934653T1 (https=) |
| SM (1) | SMT202300036T1 (https=) |
| WO (1) | WO2021239943A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
| ES2937145T3 (es) * | 2020-05-29 | 2023-03-24 | CEBINA GmbH | Azelastina como tratamiento antiviral |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3877904D1 (de) * | 1987-11-13 | 1993-03-11 | Asta Pharma Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge. |
| DE3836579A1 (de) * | 1987-11-13 | 1989-05-24 | Asta Pharma Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge |
| US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| JP2008285474A (ja) | 2007-04-17 | 2008-11-27 | Daiichi Sankyo Healthcare Co Ltd | 抗アデノウイルス剤を含有する医薬組成物 |
| US8642069B2 (en) * | 2008-08-27 | 2014-02-04 | Alexander D. Goldin | Composition and method for treating colds |
| WO2021207213A2 (en) * | 2020-04-07 | 2021-10-14 | University Of Florida Research Foundation, Incorporated | Methods to prevent sars-cov-2 infection and treat covid-19 |
| US20230142221A1 (en) * | 2020-04-10 | 2023-05-11 | Kamal Khan Mubarak | Compositions and methods for modulating ace2 receptor |
| CN113521289A (zh) * | 2020-04-16 | 2021-10-22 | 中国科学院上海药物研究所 | 15种药物有效成分在抗病毒感染中的应用 |
| ES2937145T3 (es) * | 2020-05-29 | 2023-03-24 | CEBINA GmbH | Azelastina como tratamiento antiviral |
-
2021
- 2021-05-28 ES ES21727186T patent/ES2937145T3/es active Active
- 2021-05-28 CA CA3184167A patent/CA3184167A1/en active Pending
- 2021-05-28 WO PCT/EP2021/064338 patent/WO2021239943A1/en not_active Ceased
- 2021-05-28 HU HUE21727186A patent/HUE060929T2/hu unknown
- 2021-05-28 US US17/928,422 patent/US20230201216A1/en active Pending
- 2021-05-28 AU AU2021279280A patent/AU2021279280A1/en active Pending
- 2021-05-28 PL PL21727186.5T patent/PL3934653T3/pl unknown
- 2021-05-28 KR KR1020227045014A patent/KR20230021009A/ko active Pending
- 2021-05-28 JP JP2023516644A patent/JP2023529025A/ja active Pending
- 2021-05-28 LT LTEPPCT/EP2021/064338T patent/LT3934653T/lt unknown
- 2021-05-28 SI SI202130029T patent/SI3934653T1/sl unknown
- 2021-05-28 DK DK21727186.5T patent/DK3934653T3/da active
- 2021-05-28 FI FIEP21727186.5T patent/FI3934653T3/fi active
- 2021-05-28 IL IL298543A patent/IL298543A/en unknown
- 2021-05-28 MX MX2022015074A patent/MX2022015074A/es unknown
- 2021-05-28 CN CN202180059038.4A patent/CN116406273A/zh active Pending
- 2021-05-28 US US17/333,857 patent/US11273163B2/en active Active
- 2021-05-28 EP EP21727186.5A patent/EP3934653B1/en active Active
- 2021-05-28 RS RS20230083A patent/RS63940B1/sr unknown
- 2021-05-28 SM SM20230036T patent/SMT202300036T1/it unknown
- 2021-05-28 EP EP22206040.2A patent/EP4190333A1/en active Pending
- 2021-05-28 BR BR112022023897A patent/BR112022023897A2/pt unknown
- 2021-12-27 US US17/562,973 patent/US11433080B2/en active Active
-
2022
- 2022-11-21 JO JOJO/P/2022/0319A patent/JOP20220319B1/ar active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021279280A1 (en) | 2023-01-05 |
| EP3934653A1 (en) | 2022-01-12 |
| SMT202300036T1 (it) | 2023-03-17 |
| MX2022015074A (es) | 2023-02-16 |
| PL3934653T3 (pl) | 2023-03-13 |
| US11273163B2 (en) | 2022-03-15 |
| EP4190333A1 (en) | 2023-06-07 |
| RS63940B1 (sr) | 2023-02-28 |
| HUE060929T2 (hu) | 2023-04-28 |
| EP3934653B1 (en) | 2022-11-09 |
| FI3934653T3 (fi) | 2023-03-01 |
| IL298543A (en) | 2023-01-01 |
| BR112022023897A2 (pt) | 2023-04-04 |
| KR20230021009A (ko) | 2023-02-13 |
| ES2937145T3 (es) | 2023-03-24 |
| WO2021239943A1 (en) | 2021-12-02 |
| CN116406273A (zh) | 2023-07-07 |
| CA3184167A1 (en) | 2021-12-02 |
| JOP20220319B1 (ar) | 2024-12-22 |
| JP2023529025A (ja) | 2023-07-06 |
| US11433080B2 (en) | 2022-09-06 |
| US20230201216A1 (en) | 2023-06-29 |
| US20210369730A1 (en) | 2021-12-02 |
| LT3934653T (lt) | 2023-02-27 |
| DK3934653T3 (da) | 2023-02-13 |
| US20220143040A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3955867A4 (en) | COMBINATION TREATMENT USING ELT | |
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| IL284199A (en) | Csf1r inhibitors for use in treating cancer | |
| SI3986897T1 (sl) | Inhibitor EGFR za zdravljenje raka | |
| UY37825A (es) | Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| IL274445A (en) | Adenosine pathway inhibitors for cancer treatment | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| EA201692316A1 (ru) | Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний | |
| EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
| EP4493175A4 (en) | MIRDAMETINIB TREATMENT | |
| EP3458033A4 (en) | TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR THE TARGETED TREATMENT OF PANCREAS CANCER | |
| EP3355890A4 (en) | HUMAN PLASMA CALLICINE REMEDY | |
| EP3518925A4 (en) | DUAL CLK / CDK1 INHIBITORS FOR CANCER TREATMENT | |
| EP4206080A4 (en) | DEGAZER | |
| EP4178042A4 (en) | CONNECTOR | |
| EP4008696A4 (en) | SURFACE TREATMENT AGENT | |
| EP4001364A4 (en) | Surface treatment agent | |
| EP4102649A4 (en) | CONNECTOR | |
| UA107346C2 (en) | Use of nifuratel to treat infections caused by atopobium species | |
| SI3934653T1 (sl) | Azelastin za protivirusno zdravljenje | |
| MA51821A (fr) | Inhibiteurs de la thiorédoxine réductase à utiliser dans le traitement du cancer | |
| IL311922A (en) | Heterocyclic compounds for use in the treatment of cancer | |
| EP4321590A4 (en) | Surface treatment agent | |
| EP4405334C0 (en) | Sortilin inhibitors | |
| EP4398893A4 (en) | IBOGAINE COMBINATION THERAPY |